Denmark-based Novo Nordisk announced plans to invest $113 million in production facilities at its existing 345,000 square feet site in Chartres, France.
The expansions will help Novo meet the increasing global demand for diabetes medicines. The Chartres site produces a range of the company's insulin products, including FlexPen, the world's leading insulin injection device.
The French site expansion will also grow the workforce by 20 percent. The site current employs 1,100 employees.
Read the Novo press release